Seniors Face Higher Drug Plan Costs as Subsidy Ends

The federal cushion that has kept many Medicare drug plan premiums low for two years disappears after this December. The Trump administration plans to end the Medicare Part D subsidy program in 2027.

That decision lands hard for people who have watched their monthly bills creep up while their income stayed the same. I read the announcement and felt a quiet worry settle in. Not panic. Just the kind of concern that comes from knowing how thin the margin is for so many older Americans.

The program in question is called the Part D Premium Stabilization Demonstration. It was a temporary measure created to smooth out the market after big changes to Medicare drug coverage took effect in 2024. The federal government paid insurers to help hold down the monthly premiums that seniors pay for stand-alone Part D plans. Those are the drug plans people buy if they stay on traditional Medicare instead of switching to a Medicare Advantage plan that bundles everything together.

Without that subsidy, insurers will set their 2027 prices on their own again. The Centers for Medicare and Medicaid Services said its review of next year’s bids showed that insurance companies now have enough experience with the redesigned Part D system to price their plans accurately without federal support. That may be true from a market standpoint. But it does not change the fact that many seniors will see their monthly costs rise.

The subsidy was paying an estimated $9.8 billion in 2025 and 2026 to stand-alone Part D prescription plans. It offered a $15 direct subsidy applied to base beneficiary premiums and a $35 cap to prevent sharp year-over-year increases. Now that buffer is gone. Enrollees will find out their new monthly cost later this fall when CMS releases final 2027 Medicare Advantage and Part D plan details in September.

Some officials say most beneficiaries will not see large jumps. A CMS spokesperson told Spectrum News that among the roughly quarter of Medicare beneficiaries enrolled in plans the previous demonstration impacted, over 85 percent will have access to a Part D plan that is either lower cost or less than a $10 increase next year. The agency also said every beneficiary in that group will have access to at least three prescription drug plan options with total monthly premiums of $50 or less.

But averages can hide the people who do not fit the pattern. A ten dollar increase may sound small until you are living on a fixed income and already choosing between groceries and prescriptions. And not everyone will land in that 85 percent. Some will face bigger jumps. The national average monthly bid amount, a measure used to calculate government subsidies for plans, will be $296.05 in 2027. That number matters because it shapes what insurers charge and what the government pays toward each plan.

It is important to be clear about what is not changing. Medicare Part D itself is not ending. The drug benefit continues. The out-of-pocket spending cap that limits how much seniors pay each year for covered drugs also stays in place. That cap is set at $2,100 in 2026 and will rise to $2,400 in 2027 under the Inflation Reduction Act. The separate Low-Income Subsidy program, often called Extra Help, is also unaffected. People who qualify for Extra Help will continue to receive zero-dollar premiums or reduced copays under current rules.

What ends is the temporary federal cushion that made stand-alone Part D plans cheaper for the past two years. The program was always meant to be temporary. But it was widely expected to run through 2027. Instead, federal officials are letting it expire on December 31, 2026, a year earlier than many anticipated.

Senior advocacy groups and Democrats have already signaled they will contest the decision. They argue that ending the subsidy will harm vulnerable populations who rely on predictable drug costs to manage chronic conditions. AARP noted that canceling the program sunsets a Biden-era initiative that helped tens of millions of original Medicare enrollees keep premiums in check.

Dr. Mehmet Oz, administrator of CMS, said in a social media post that the demonstration was wasting taxpayer money now that the market has stabilized. He said insurers have sufficient experience pricing plans under the new rules and no longer need federal support. That logic makes sense if you are focused on government spending. It makes less sense if you are the person opening your mailbox in September and seeing a higher premium for the same coverage.

I keep thinking about what this means for ordinary people. Not analysts. Not insurers. The retiree in Ohio who takes insulin and a blood pressure pill. The widow in Florida who budgets her Social Security check down to the dollar. For them, a subsidy ending is not a policy shift. It is a bill that goes up.

The final 2027 plan details will be released in September. Until then, seniors can only wait and watch. Many will use the annual enrollment period this fall to shop for a different plan. Some will find a cheaper option. Others will not. And that is the quiet worry I cannot shake. Not because the system is collapsing. But because for millions of seniors, the math is about to get harder.